

Supplementary Table 1. Criteria for LVAD implantation in Korea

Indications	<ol style="list-style-type: none"> 1. Bridge to transplantation (BTT) in end-stage heart failure patient registered as a heart transplantation candidate 2. End-stage heart failure patient ineligible for heart transplantation and has severe symptoms > 2 months despite medication including beta blockers or mechanical circulatory devices such as IABP and ECMO, and fulfills one or more of the following: <ol style="list-style-type: none"> a. LVEF < 25% or equivalent evidence of ventricular dysfunction with peak VO_2 < 12 mL/kg/min (14 mL/kg/min in case of beta blocker intolerance) or an equivalent exercise test result b. Unable to discontinue intravenous inotropes c. Progressive renal or hepatic dysfunction caused by heart failure (PCWP \geq 20 mmHg and either systolic blood pressure \leq 90 mmHg or cardiac index \leq 2.0 L/min/m²)
Contraindications	<p>Contraindications for each case are debated by the official expert panels.</p> <ol style="list-style-type: none"> 1. End-stage renal disease receiving permanent dialysis therapy 2. Irreversible organ dysfunction of the kidneys, liver, or lung 3. Severe brain damage 4. Sepsis 5. Contraindication to long-term anticoagulation 6. Comorbidity limiting life expectancy such as advanced cancer

LVAD, left ventricular assist device; IABP, intra-aortic balloon pump; ECMO, extracorporeal membrane oxygenation; LVEF, left ventricular ejection fraction; VO_2 , oxygen consumption; PCWP, pulmonary capillary wedge pressure.